Cilloni D, Saglio G. CML: A model for targeted therapy. Best Pract Res Clin Haematol 2009;22:285–94.
Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol 2009; 22:303–13.
Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E. Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opin Biol Ther 2009;9:207–20.
Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223–35.
Van Meerten T, Hagenbeek A. CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med. 2009;67:251–9.
Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222–32.
Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964–79.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.
Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301–8.
Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 2010;277:309–15.
Chau I, Cunningham D. Treatment in advanced colorectal cancer: What, when and how? Br J Cancer 2009;100:1704–19.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–8.
Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors. Similar but different? Anticancer Drugs 2009;20:856–66.
Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357–60.
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies. Canadian recommendations. Current Oncol 2009;16:16–26.
Pérez-Soler R, Delord JP, Halpern A, Kelly K, Sureda BM, Von Pawel J, et al. HER1/EGFR inhibitor-associated rash; future directions for management and investigation outcomes from HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345–56.
Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470–81.
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838–47.
Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor- 2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009;31:2332–48.
Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for inhibition. MAbs 2010;2:165–75.
Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;8:507–18.
Patel NS, Muneer A, Blick C, Arya M, Harris AL. Targeting vascular endothelial growth factor in renal cell carcinoma. Tumor Biol 2009;30:292–9.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.
Rini BI. Metastatic renal cell carcinoma: Many treatment options, one patient. J Clin Oncol 2009:27::3225–34.
Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8–18.
Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine. Focus on breast and colorectal cancer. Anticancer Drugs 2009;20:217–29.
Comella P, Franco L, Casaretti R, De Portu S, Menditto E. Emerging role of capecitabine in gastric cancer. Pharmacotherapy 2009;29:318–30.
Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95–9.
O'Brien MER. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008;19:1–7.
Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:152–8.
Gossage L, Eisen T. Targeting multiple kinase pathways. Change in paradigm. Clin Cancer Res 2010;16:1973–8.
Ellis LM, Hicklin DJ. Resistance to targeted therapies: Refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471–8.
Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti- CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206–13.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–9.
Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, et al. Clinical cancer advances 2009: Major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:6052–69.